despite bitter objections and no votes from the czech republic hungary, romania and slovakia. the plan only addresses a tiny fraction of the migrants flowing in to europe. some 35,000 entered croatia in just six days last week. the drug company that s been taking heat for a 5,000% overnight increase on a critical prescription drug is now rolling that hike back. the medication is called daraprim, and is used to treat people with weakened immune systems from pregnant women to people with aids. the ceo of turing pharmaceutical, a 32-year-old former hedge fund manager, initially justified the price hike claiming that the money was needed for research and development. in response to all of this attention, and doctors and patient groups saying they can t access this drug are you going to change the price? no. the ceo now acknowledges that mistakes were made with respect to helping people understand the huge increase.
turing pharmaceutical ceo seems to be rethinking his stance on a drug used to treat a life threatening parasitic infection. on monday you may recall he gave a resounding no when cnbc s meg terrell asked if he would roll back the 5,000% price hike of daraprim. he initially said the increase would go to researching a new pill. but, some medical experts, they are reskeptical. we don t need another drug in this space. and there s no indication that this guy has any idea how to do drug research and development. and in a phone interview with nbc news andrea mitchell yesterday he defended the price hike, but he also hinted at a decrease. the price of daraprim did not create a wildly profitable company. turing pharmaceuticals, even at our new price, is barely a break-even company. we ll lower it to a point where turing pharmaceuticals is a